Postmenopausal osteoporosis. Postmenopausal osteoporosis
Conditions
Interventions
Intervention 1: Intervention group: Vomigone tablets manufactured by Dinah's pharmaceutical company containing 470 ± 30 mg of standarized rhizome powdered of ginger (Zingiber officinale) twice-daily w
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: Natural menopause Age 45 and above Menstrual cessation for 12 consecutive months low bone density (Score T minus 2.5 and lower) No history of fracture
Exclusion criteria
Exclusion criteria: Use Contraceptive Pills or Corticostroids During Study Kidney disease or failure Metastatic bone disease Taking medications that affect bone metabolism other than taking calcium-D supplements or Alendronate that are given to all subjects with the same dose. Malignancy coagulation disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Evaluating the quality of life at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: The Menopause Specific Quality of Life Questionnaire.;Body composition. Timepoint: Evaluating the Body composition at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Body composition analyzer.;Bone mineral density. Timepoint: Measuring serum Bone mineral density at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Dual X-ray absorptiometry (DXA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Osteocalcin. Timepoint: Measuring serum osteocalcin at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Biochemical assay.;Procollagen type 1 amiNo-terminal Propeptide. Timepoint: Measuring serum Procollagen type 1 amiNo-terminal Propeptide at the beginning of the study (before the intervention) and 6 months after the intervention began. Method of measurement: Biochemical assay.;Caboxy-Terminal cross-linked telopeptides of type 1 collagen. Timepoint: Measuring serum Caboxy-Terminal cross-linked telopeptides of type 1 collagen at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Biochemical assay.;MiR-422a (micro-RNA). Timepoint: Measuring serum miR-422a (micro-RNA) at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Biochemical assay.;MiR-133a (micro-RNA). Timepoint: Measuring serum miR-133a (micro-RNA) at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Biochemical assay.;MiR-21 (micro-RNA). Timepoint: Measuring serum miR-21 (micro-RNA) at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Biochemical assay.;MiR-503 (micro-RNA). Timepoint: Measuring serum MiR-503 (micro-RNA) at the beginning of the study (before the intervention) and 4 months after the intervention began. Method of measurement: Biochemical assay. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNeda Dolatkhah
Tabriz University of Medical Sciences
Outcome results
None listed